Mehta B M, Spear F G, Whittington J R
Curr Med Res Opin. 1980;7(1):14-22. doi: 10.1185/03007998009116509.
A double-blind trial was carried out in 47 patients with depression to compare the effectiveness of 30 mg mianserin, 60 mg mianserin and 50 mg sustained-release amitriptyline, each given as a single dose at night over a period of 4 weeks. Hamilton Rating Scale scores showed significant, progressive improvement from Week 1 with all three regimens. Although the differences between the groups were not significant, the greatest improvement occurred after 60 mg mianserin daily and the order of effectiveness was consistent for various Hamilton Rating Scale items. Patient self-assessment, using visual analogue scales, gave similar results to the Hamilton Rating Scale with significant, progressive improvement in all groups. Once again, a consistent order of effectiveness was evident with most of the items, the greatest improvement being noted with 60 mg mianserin daily and the least with 30 mg mianserin daily. There was a considerable reduction in the number of reports of symptoms recorded before the trial during treatment in all groups. The only increase in symptoms possible drug-related was of blurred vision in patients receiving amitriptyline.
对47名抑郁症患者进行了一项双盲试验，以比较30毫克米安色林、60毫克米安色林和50毫克缓释阿米替林的疗效，每种药物均在夜间单次给药，为期4周。汉密尔顿评定量表评分显示，在第1周后，所有三种治疗方案均有显著的、逐步的改善。尽管各组之间的差异不显著，但每日60毫克米安色林后的改善最大，且不同汉密尔顿评定量表项目的疗效顺序一致。使用视觉模拟量表进行的患者自我评估结果与汉密尔顿评定量表相似，所有组均有显著的、逐步的改善。同样，大多数项目的疗效顺序一致，每日60毫克米安色林的改善最大，每日30毫克米安色林的改善最小。在治疗期间，所有组在试验前记录的症状报告数量都有相当大的减少。唯一可能与药物相关的症状增加是接受阿米替林治疗的患者出现视力模糊。
